nal-IRI+5-FU/LV versus 5-FU/LV in post-gemcitabine metastatic pancreatic cancer: Randomized phase 2 trial in Japanese patients.

Makoto UenoShoji NakamoriKazuya SugimoriMasashi KanaiMasafumi IkedaMasato OzakaMasayuki FurukawaTakuji OkusakaKen KawabeJunji FuruseYoshito KomatsuHiroshi IshiiAtsushi SatoSatoshi ShimizuPriti ChughRui TangTatsuya Ioka

Published in: Cancer medicine (2020)

In conclusion, clinically meaningful and statistically significant gains in investigator-assessed PFS and ORR were observed with nal-IRI+5-FU/LV versus 5-FU/LV in Japanese patients, with no new or unexpected safety signals. (Clinicaltrials.gov ID: NCT02697058).

Keyphrases

squamous cell carcinoma
small cell lung cancer
double blind
randomized controlled trial
placebo controlled
study protocol